This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.
A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. percent of the patients treated between 2005 and 2009 to 6.82% of the patients treated between 2015 and 2019. million U.S.
BACKGROUND:Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined.METHODS:This retrospective observational cohort study evaluated 50 316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan. were women.
It’s well known that heart disease is the U.S.’s s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. trillion, representing 4.6% of US GDP. If applied across the U.S.,
Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.
Reliability of self-reported risk factors was high in overweight (F1 0.81) and diabetes (F1 0.71), moderate in hearing impairment (F1 0.59) and hypertension (F1 0.56) and low in hypercholesterolemia (F1 0.49) and kidneydisease (F1 0.25).
A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. percent of the patients treated between 2005 and 2009 to 6.82% of the patients treated between 2015 and 2019. million U.S.
This study evaluates the outcomes in patients admitted for HF with and without hyperkalemia.Methods:We used the Nationwide Readmissions Database (NRD) from 2016-2019, extracting adult patients with a primary diagnosis of HF who were admitted between January and November of each year. Survey procedures were applied using SAS 9.4.Results:We
million (2019) and projected to reach 4.90 million by 2030 according to the Global Burden of Disease Study. Autoimmune diseases are increasingly associated with chronic conditions and may modify risks by altering underlying pathophysiology. to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27
Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]
Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetickidneydisease, hypertension, and nephropathy progression. A Pioneering Journey: The Life and Legacy of Dr. George L. Bakris Dr. George L. When I heard of his passing, I felt quite sad.
11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 2019 Sep 10;140(11):e649-e650] [published correction appears in Circulation. Published 2019 Feb 28.
2019 Apr 2;321(13):1261-1274. Overall, it appears that rhythm control strategy in AF may be better in those with heart failure and in those with associated cardiovascular conditions and early AF. doi: 10.1001/jama.2019.0693. PMID: 30874766; PMCID: PMC6450284.
It is highly recommended to screen for liver fibrosis in patients with Type 2 diabetes mellitus (T2DM) and elevated liver enzymes using the fibrosis-4 (FIB-4) score.However, this recommendation does not extend to patients with chronic heart failure (CHF) who do not have T2DM. 1.45), cardiovascular mortality (HR: 1.80, 95% CI: 1.49-2.17),
In multivariate regression analysis, the factors independently associated with a greater risk of readmission within 90 days were hypercoagulation (1.359 [95%CI, 1.1274‐1.45]), opiod abuse and dependence (1.353 [95%CI, 1.238‐1.478]), chronic kidneydisease (1.347 [95%CI, 1.316‐1.379]), liver disease (1.318 [95% CI, 1.26‐1.378]),
Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. female, 22.1% female, 22.1%
Methods:Deidentified administrative discharge data included all individuals admitted to SC hospitals between 2010 and 2019 with ICD-9/10 codes for ischemic stroke. This study aims to assess sociodemographic profile and stroke risk factors among individuals residing in FDs within the predominantly rural state of South Carolina (SC).Methods:Deidentified
Pseudotime progression associated with higher HbA1c, BMI, and GBM, and lower insulin sensitivity and cortical oxidative metabolism.CONCLUSION These early structural and metabolic changes in T1D kidneys may precede clinical DKD.TRIAL REGISTRATION ClinicalTrials.gov NCT04074668.FUNDING
Written by Jesse McLaren An 80 year old patient with diabetes/hypertension/ cirrhosis had a recent increase in candesartan for their hypertension, and was also on spirolactone and nadolol. Acute hyperkalemia in the emergency department: a summary from a KidneyDisease: Improving Global Outcomes conference. References 1.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content